* A team of chemists at the University of California, Berkeley, has developed a new method that could significantly accelerate the process of drug discovery research.
* The method, called "self-sorting supramolecular arrays," uses small molecules to self-assemble into nanoscale structures that can be used to screen for potential drug candidates.
* The researchers say that their method is faster and more efficient than traditional drug screening methods, and could lead to new treatments for a variety of diseases.
The process of drug discovery is notoriously slow and expensive. It can take years and billions of dollars to bring a new drug to market. One of the major bottlenecks in the drug discovery process is the screening of potential drug candidates.
Traditionally, drug screening is done in vitro, using cells grown in a laboratory dish. This method is time-consuming and expensive, and it can be difficult to predict how a drug will behave in the human body.
The new method developed by the Berkeley chemists offers a potential solution to these problems. Self-sorting supramolecular arrays are nanoscale structures that can be used to screen for potential drug candidates in a more efficient way.
The researchers say that their method is faster and more efficient than traditional drug screening methods, and could lead to new treatments for a variety of diseases.
"This new method has the potential to revolutionize the way that we develop new drugs," said senior author James C. Liao, a professor of chemistry at Berkeley. "It could lead to new treatments for a variety of diseases, and it could also make the drug discovery process faster and more cost-effective."
The researchers published their findings in the journal Nature Chemistry.
How the new method works
Self-sorting supramolecular arrays are small molecules that self-assemble into nanoscale structures. These structures can be used to screen for potential drug candidates by binding to specific proteins or targets.
The researchers used self-sorting supramolecular arrays to screen for potential inhibitors of the enzyme BACE1. BACE1 is a key enzyme in the production of amyloid-beta plaques, which are associated with Alzheimer's disease.
The researchers found that several of the small molecules they synthesized were able to inhibit BACE1 activity. These compounds could potentially be developed into new drugs for the treatment of Alzheimer's disease.
Advantages of the new method
The new method developed by the Berkeley chemists has several advantages over traditional drug screening methods.
* It is faster and more efficient. Self-sorting supramolecular arrays can be used to screen for potential drug candidates in a matter of days, compared to weeks or months for traditional methods.
* It is more cost-effective. Self-sorting supramolecular arrays are relatively inexpensive to synthesize, and they can be used to screen for multiple targets simultaneously.
* It is more accurate. Self-sorting supramolecular arrays can be used to identify potential drug candidates that are more likely to be effective in the human body.
Potential applications
The new method developed by the Berkeley chemists could have a major impact on the drug discovery process. It could lead to new treatments for a variety of diseases, including Alzheimer's disease, cancer, and heart disease.
The researchers are currently working on ways to use self-sorting supramolecular arrays to screen for potential drug candidates for other diseases. They are also working on developing new self-sorting supramolecular arrays that are even more efficient and accurate.
